Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2025-12-05 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于公司产品获批的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a product (2'-Fucosyllactose) by the National Health Commission of China. It includes details about the product, regulatory approval, and potential impact on the company. The document is short (1059 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an announcement of a regulatory approval event rather than a financial report or management update. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-12-05 Chinese
关于在下属子公司之间调剂担保额度及为全资子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company (亿帆医药股份有限公司) regarding the progress of guarantee quota adjustments and guarantees provided to its wholly-owned subsidiaries. It details the internal adjustments of guarantee limits among subsidiaries, specific guarantee contracts signed with banks, financial data of the subsidiaries, and board and shareholder meeting approvals related to these guarantees. The document does not contain comprehensive financial statements or detailed financial performance analysis but focuses on updates about financing guarantees and related contractual arrangements. It is not an annual or interim report, earnings release, or audit report. It is not a regulatory certification or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it provides updates on the company's financing activities, specifically guarantees and credit facilities involving subsidiaries.
2025-12-05 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2025 年第三季度报告" which translates to "2025 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the third quarter of 2025. The document includes comprehensive financial figures, management statements ensuring accuracy, and detailed explanations of financial metrics and changes. It also includes shareholder information and other corporate disclosures relevant to the quarter. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a full quarterly financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2025
2025-10-30 Chinese
第九届董事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolutions passed at the company's ninth board of directors' second meeting, including approval of the 2025 third quarter report and an asset impairment provision proposal. It references the 2025 third quarter report and related announcements but does not contain the actual financial statements or detailed financial data itself. The document is short (869 characters) and serves as a formal notice of board decisions rather than the report itself. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and notices that do not fit other categories.
2025-10-30 Chinese
关于2025年前三季度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about the asset impairment provision for the first three quarters of 2025. It details the amounts of impairment provisions made, the accounting standards followed, and the impact on profits. It includes board resolutions and audit committee approvals related to this provision. The document is relatively short (2271 characters) and focuses on a specific financial adjustment rather than presenting a full financial report or comprehensive quarterly results. It does not contain full financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR). Instead, it is a regulatory announcement about a specific accounting action and board decisions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-30 Chinese
关于全资子公司参与全国药品集中采购拟中选的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1028 characters) from a company about its wholly owned subsidiary's participation in a national drug procurement tender and the preliminary selection results. It includes product details, expected impact, and risk warnings. There is no financial data, no detailed report, no management discussion, no voting results, no regulatory certification, and no mention of a report being attached or published. The document is an official announcement about a business event related to procurement participation and expected impact, which fits best under a general regulatory announcement category rather than a detailed financial or management report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-10-29 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.